Actinogen Medical Limited has released a press release.
ACW FY2026 results and outlook
Earlier from Actinogen Medical
- June 2026 Quarterly activity report & Appendix 4C
- Xanamem depression trial published in British J Psychiatry
- ACW third positive XanaMIA trial data committee review
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program